Company profile

Breath Therapeutics company profile

Breath Therapeutics – a Zambon Group Company is pursuing groundbreaking therapies by unleashing the true potential of inhaled drug delivery. Their approach combines novel formulations of existing drugs with cutting-edge inhalation technology for the treatment of rare respiratory diseases with high unmet medical need. They are developing drug-device combinations designed to rapidly deliver high concentrations of drugs to the site of action in the lung. Their approach increases effective dosing in the lung while minimizing systemic exposure which could lead to new treatment solutions with enhanced efficacy and safety.

Business identity

Operating status
Closed
Company type
For Profit
Employee range
00001-00010 employees
Revenue range
$10K+
Founded
2016-01-01

Headquarters

Headquarters
Bayern, Germany, Munich
Postal code
80639
Country code
DE
Continent
Europe

Capital profile

Funding and company signals

Funding stage
M And A
Funding rounds
1
Total equity funding
$45.9M
Last funding
Series A / $45.9M / 2017-03-08
Last equity funding
Series A / $45.9M
Investors
3
Lead investors
2
Founders
4
Articles
10
Exited on
2019-07-25

Founders and investors

Founders

Anne BurgerGerhard BörnerJens StegemannOliver Denk

Lead investors

GimvSofinnova Partners

Investors

Gilde HealthcareGimvSofinnova Partners

People at this company

Preview only. Contact details are available after you sign in.

Log in to view people and contact details at this company

Contact information and company affiliations may no longer be accurate. Verify details before reaching out.

Shipment data

Explore detailed shipment data

Sign in to view shipment history, products, suppliers, and trade lanes for this company.

Log in to view shipment data

Shipment records and coverage can change as the dataset is updated.